In Q1 2026, Tivic Health Systems formalized its transformation into Valion Bio, Inc., reflecting a strategic shift from a legacy medical device business to biopharmaceutical innovation anchored by Entolimod, a Phase III TLR5 agonist. The company complements this pivot with its CDMO subsidiary Velocity Bioworks aiming to support internal pipeline and third-party manufacturing. Despite ongoing net losses, Valion Bio maintains a strong liquidity position with current assets exceeding liabilities by more than threefold, enabling continued clinical development and operational execution. The path forward hinges on Entolimod's regulatory progress and commercial traction in niche acute radiation syndrome markets.